Skip to main content
. 2023 May 25;9(6):e16665. doi: 10.1016/j.heliyon.2023.e16665

Fig. 3.

Fig. 3

Dot plot demonstrating the distribution of CRP level in: (a) admitted patients treated with Tocilizumab and non-admitted individuals with no acute disease, (b) in patients admitted due to infectious disease, and (c) in patients admitted due to non-infectious disease.